Curis, Inc. (CRIS)
| Market Cap | 16.83M -31.9% |
| Revenue (ttm) | 7.06M -36.9% |
| Net Income | -21.17M |
| EPS | -1.33 |
| Shares Out | 39.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 898,606 |
| Open | 0.3800 |
| Previous Close | 0.4210 |
| Day's Range | 0.3800 - 0.4468 |
| 52-Week Range | 0.3784 - 2.5680 |
| Beta | 3.08 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+3,225.42%) |
| Earnings Date | Aug 4, 2026 |
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refra... [Read more]
Financial Performance
In 2025, Curis's revenue was $9.44 million, a decrease of -13.43% compared to the previous year's $10.91 million. Losses were -$7.58 million, -82.53% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price target is $14.0, which is an increase of 3,225.42% from the latest price.
News
Curis Proxy statement: Proxy filing
Curis filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Curis Slides: Corporate presentation
Curis has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Curis Proxy statement: Proxy filing
Curis filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Curis Transcript: AGM 2026
The meeting covered five key proposals, including director elections, executive compensation, auditor ratification, and an increase in authorized shares, all of which were approved by majority vote. Voting procedures and risks related to forward-looking statements were also addressed.
Curis reports Q1 EPS ($1.25), consensus (29c)
Reports Q1 revenue $0, consensus $1.86M. As of March 31 Curis’s (CRIS) cash and cash equivalents totaled $15.0M, and the Company had approximately 40.0 million shares of common stock outstanding.
Curis sees cash and proceeds enough for operations into second half of FY27
Curis (CRIS) believes its cash and cash equivalents as of March 31 of $15.0M, together with anticipated gross proceeds of up to an additional $20.2M from the exercise of the…
Curis Earnings Call Transcript: Q1 2026
Advanced registrational and proof-of-concept studies in PCNSL and CLL, with steady enrollment and promising early data. Net loss increased due to PIPE financing, but cash runway extends into 2027, contingent on warrant exercises.
Curis Earnings release: Q1 2026
Curis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Curis Quarterly report: Q1 2026
Curis has published its Q1 2026 quarterly earnings report on May 12, 2026.
Curis Provides First Quarter 2026 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT...
Curis Proxy statement: Proxy filing
Curis filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Curis Proxy statement: Proxy filing
Curis filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Curis Slides: Corporate presentation
Curis has posted slides in relation to its latest quarterly earnings report, which was published on March 30, 2026.
Curis Earnings Call Transcript: Q4 2025
Q4 2025 saw a swing to net income due to a one-time gain from the Erivedge sale, with R&D and G&A expenses down year-over-year. PCNSL and CLL studies are prioritized, with initial CLL data expected at ASH 2026 and operations funded into H2 2027.
Curis Annual report: Q4 2025
Curis has published its Q4 2025 annual report on March 19, 2026.
Curis Earnings release: Q4 2025
Curis released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
Curis Transcript: EGM 2026
Four key proposals—including increasing authorized shares, approving stock conversions and warrants, and adopting a new incentive plan—were presented and all passed by majority vote. Final results will be filed in a Form 8-K.
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and ...
Curis Proxy statement: Proxy Filing
Curis filed a proxy statement on February 19, 2026, providing details for shareholder voting and corporate governance matters.
Curis Registration statement: Registration Filing
Curis filed a registration statement on February 13, 2026, providing details about a securities offering with the SEC.
Curis Proxy statement: Proxy Filing
Curis filed a proxy statement on February 9, 2026, providing details for shareholder voting and corporate governance matters.
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology ...
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FL...